文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

ACTG A5288 筛查中 HIV-1 耐药谱的多样性:资源有限地区二线 ART 失败者的研究

Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究在低收入和中等收入国家筛查准备进入三线 ART 试验的候选者,对 653 例二线 ART 失败者进行耐药基因型检测。78% 对至少一种药物耐药,26% 对三类常用药物均耐药,但对依曲韦林(78%)和达芦那韦/利托那韦(97%)的敏感性较高。耐药谱高度多样,强调耐药检测和新抗逆转录病毒药物的可及性。

要点

  • 二线 ART 失败者中 78% 存在至少一种药物耐药,26% 对三类常用药物均耐药。
  • 对至少一种二线方案保持敏感者占 59%,对达芦那韦/利托那韦敏感者占 97%。
  • 女性、年轻、较高 CD4 最低值及曾用洛匹那韦/利托那韦者二线方案敏感性更高。

核心结论

  • 资源有限地区三线 ART 筛查候选者的 HIV 耐药谱高度多样,从无耐药到三类药物均耐药,需耐药检测和新药可及。

研究设计与样本

  • 对 ACTG A5288 三线 ART 试验筛查候选者进行耐药基因型检测,分析 653 例二线 ART 失败者的耐药谱及相关因素。

主要发现

  • 653 例中 508 例(78%)对至少一种药物耐药,133 例(20%)对至少一类药物耐药,206 例(32%)对至少两类药物耐药,169 例(26%)对三类常用药物均耐药。
  • 对至少一种二线方案保持敏感者占 59%,对依曲韦林敏感者占 78%,对达芦那韦/利托那韦敏感者占 97%。
  • 二线方案敏感性在女性、年轻个体、较高 CD4+ T 细胞最低值及曾用洛匹那韦/利托那韦者中显著更高,在曾用奈韦拉平者中更低。

临床怎么用

  • 对二线 ART 失败者应进行耐药检测以指导三线方案选择,并关注达芦那韦/利托那韦和依曲韦林等药物的敏感性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human immunodeficiency virus (HIV) drug resistance profiles are needed to optimize individual patient management and to develop treatment guidelines. Resistance profiles are not well defined among individuals on failing second-line antiretroviral therapy (ART) in low- and middle-income countries (LMIC). METHODS: Resistance genotypes were performed during screening for enrollment into a trial of third-line ART (AIDS Clinical Trials Group protocol 5288). Prior exposure to both nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs and confirmed virologic failure on a protease inhibitor-containing regimen were required. Associations of drug resistance with sex, age, treatment history, plasma HIV RNA, nadir CD4+T-cell count, HIV subtype, and country were investigated. RESULTS: Plasma HIV genotypes were analyzed for 653 screened candidates; most had resistance (508 of 653; 78%) to 1 or more drugs. Genotypes from 133 (20%) showed resistance to at least 1 drug in a drug class, from 206 (32%) showed resistance to at least 1 drug in 2 drug classes, and from 169 (26%) showed resistance to at least 1 drug in all 3 commonly available drug classes. Susceptibility to at least 1 second-line regimen was preserved in 59%, as were susceptibility to etravirine (78%) and darunavir/ritonavir (97%). Susceptibility to a second-line regimen was significantly higher among women, younger individuals, those with higher nadir CD4+ T-cell counts, and those who had received lopinavir/ritonavir, but was lower among prior nevirapine recipients. CONCLUSIONS: Highly divergent HIV drug resistance profiles were observed among candidates screened for third-line ART in LMIC, ranging from no resistance to resistance to 3 drug classes. These findings underscore the need for access to resistance testing and newer antiretrovirals for the optimal management of third-line ART in LMIC.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wallis CL, Hughes MD, Ritz J, et al. Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings. Clin Infect Dis. 2020. PMID: 31724034. doi:10.1093/cid/ciz1116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。